Dual incretin therapy, what makes tirzepatide different?

Tirzepatide gets called a dual incretin therapy, and the phrase sounds like marketing. It is a description of what the drug does, and it is how the NHS puts it.

The NHS states: "It's a dual agonist that activates the gut hormone receptors GLP-1 and GIP to increase the levels of these hormones in your body."

What dual means here

Dual means two receptors. The NHS names them as GLP-1 and GIP, so a drug that acts on only the first is a different kind of product from one that acts on both, and that is the practical meaning of the difference. Nothing in the sentence says more than that, so be wary of anyone who claims it says more.

MedlinePlus (NIH) places the drug in a category: "Tirzepatide is in a class of medications called incretin mimetics." Put the two sources together and the term has two parts: MedlinePlus (NIH) places tirzepatide in the incretin mimetics class, and the NHS says it works through two receptors, GLP-1 and GIP.

Further reading on tirzepatide and obesity

The MedlinePlus drug information on tirzepatide injection is the fuller reference. For the condition it is used for, see the MedlinePlus obesity overview, the Cleveland Clinic page on weight control and obesity and the NHS guidance on overweight and obesity in adults.

Routine versus a red flag

A provider explaining tirzepatide as acting on GLP-1 and GIP is saying something the NHS also says. A provider describing it with vague promises and no mention of how it works is giving you less than a public health source does for free.

Ask for the two receptors in plain words

Ask them to explain in their own words what the two receptors are and why they matter for your situation. If the explanation matches the NHS wording, you are being told the same thing the public record says.